Abigail Kacpura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abigail Kacpura has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kathryn Gunther
University of Texas Health Science Center at Houston
2 shared publications - Laura Schoch Farach
Department of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston) and Children's Memorial Hermann Hospital, Houston, Texas
2 shared publications - Marta Frigeni
Division of Medical Genetics Zucker School of Medicine at Hofstra/Northwell Great Neck New York USA
2 shared publications
Latest Publications
- 14 February 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (6) , 1831-1835
Clinical and biochemical outcomes in cobalamin C deficiency with use of high‐dose hydroxocobalamin in the early neonatal period
This case report describes a patient with early‐onset cobalamin C deficiency who was started on treatment with high‐dose parenteral hydroxocobalamin after diagnosis at 13 days of life. Prior to diagnosis, initial presenting symptoms included poor feeding, lethargy, apneic episodes, hypothermia, and hypotonia; these symptoms resolved after initiation of medication. Methylmalonic acid and homocysteine levels were trended and significantly improved with treatment. She was maintained on 2 mg/kg/day dosing of hydroxocobalamin. No adverse effects to treatment were observed. At the time of this report, the patient was 19 months of age; she had not manifested common findings of early‐onset cobalamin C deficiency, including microcephaly, poor feeding, growth abnormalities, hypotonia, seizures, maculopathy, or neurodevelopmental delay. This report suggests that early initiation of high‐dose hydroxocobalamin is safe and effective.
- 14 February 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (6) , 1831-1835
Clinical and biochemical outcomes in cobalamin C deficiency with use of high‐dose hydroxocobalamin in the early neonatal period
This case report describes a patient with early‐onset cobalamin C deficiency who was started on treatment with high‐dose parenteral hydroxocobalamin after diagnosis at 13 days of life. Prior to diagnosis, initial presenting symptoms included poor feeding, lethargy, apneic episodes, hypothermia, and hypotonia; these symptoms resolved after initiation of medication. Methylmalonic acid and homocysteine levels were trended and significantly improved with treatment. She was maintained on 2 mg/kg/day dosing of hydroxocobalamin. No adverse effects to treatment were observed. At the time of this report, the patient was 19 months of age; she had not manifested common findings of early‐onset cobalamin C deficiency, including microcephaly, poor feeding, growth abnormalities, hypotonia, seizures, maculopathy, or neurodevelopmental delay. This report suggests that early initiation of high‐dose hydroxocobalamin is safe and effective.
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S144-S145
Clinical and biochemical outcome with parenteral hydroxocobalamin mega-dosing in cobalamin C deficiency
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S144-S145
Clinical and biochemical outcome with parenteral hydroxocobalamin mega-dosing in cobalamin C deficiency